Archive
Here you can find the archive of all Press Releases prior to 2018
Filter by date:
Showing 732 press releases before 2019
-
European Commission approves Imfinzi for locally-advanced, unresectable NSCLC
-
Farxiga achieved a positive result in the Phase III DECLARE-TIMI 58 trial, a large cardiovascular outcomes trial in 17,000 patients with type-2 diabetes
-
AstraZeneca presents further data showing the interconnectivity between cardiovascular and renal risks in diabetes at EASD 2018
-
Fasenra shows consistent safety and sustained efficacy in long-term Phase III BORA trial in severe eosinophilic asthma
-
The Lancet Respiratory Medicine publishes first Phase III trial for PT010 triple combination therapy in moderate to very severe chronic obstructive pulmonary disease
-
US FDA approves Lumoxiti (moxetumomab pasudotox-tdfk) for certain patients with relapsed or refractory hairy cell leukaemia
-
AstraZeneca to present Fasenra long-term safety and efficacy data at European Respiratory Society International Congress 2018
-
Tezepelumab granted Breakthrough Therapy Designation by US FDA
-
Update on TULIP 1 Phase III trial for anifrolumab in systemic lupus erythematosus
-
European Commission approves new easy-to-use, once-weekly Bydureon BCise device for patients with type-2 diabetes
Latest articles and press releases
All of our latest press releases and articles are available to explore
Contact us
Email the Global Media Relations team at:
Gonzalo Viña
Head of Global Media Relations
+44 203 749 5916
Rob Skelding
Director Global Media Relations (Oncology)
+44 203 749 5821
Rebecca Einhorn
Director Global Media Relations (Oncology)
+1 301 398 1802
Matthew Kent
Director Global Media Relations (BioPharmaceuticals)
+44 203 749 5906
Angela Fiorin
Director Global Media Relations (BioPharmaceuticals)
+44 122 334 4690
Jennifer Hursit
Manager Global Media Relations
+44 203 749 5762
Christina Malmberg Hägerstrand
Media Relations Director, Sweden and Nordic-Baltic
+46 855 253 106
